← All trials
NCT06879041
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 10, 2025
- Primary completion
- Apr 16, 2029
- Completion date
- Apr 16, 2029
- First posted
- Mar 17, 2025
- Last posted
- Jul 23, 2025
- Enrollment
- 134
- Arms / groups
- 10 / —
- Source
- AACT · ctgov ingestion
Sponsors
- AstraZenecaLead sponsor
- ParexelCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.